Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
20 Fibroid Trials
Power is an online platform that helps thousands of Fibroid patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Relugolix for Uterine Fibroids
Dublin, OhioThe purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) or with moderate-to-severe pain associated with endometriosis.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 50
Sex:Female
Key Eligibility Criteria
Disqualifiers:Cushing's, Rheumatoid Arthritis, CKD, Others
Must Be Taking:Vitamin D
1000 Participants Needed
Relugolix Combination Therapy for Birth Control
Columbus, OhioThe purpose of this study is to assess the contraceptive efficacy of relugolix combination therapy.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18 - 50
Sex:Female
1020 Participants Needed
QL Block for Postoperative Pain in Fibroid Surgery
Beachwood, OhioThis study aims to determine the efficacy of a quadratus lumborum (QL) block in decreasing postoperative pain in patients undergoing myomectomy for uterine fibroids. A QL block is a temporary anesthetic injection in the quadratus lumborum muscle, a muscle in the lower back, that has been previously shown to significantly reduce postoperative pain levels in patients undergoing abdominal and pelvic surgery. Because of its demonstrated effects, the QL block is becoming a standard of anesthesia and surgical care. Since participants will be undergoing a myomectomy procedure, the investigators believe that participants may qualify to participate in this study. The investigators will be comparing patients who receive the QL block (in addition to standard anesthesia and postoperative pain care) with patients who do not receive the QL block (in addition to standard care). The participants will be randomly assigned to one of the two groups and may or may not actually receive the block.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 45
Sex:Female
Key Eligibility Criteria
Disqualifiers:Anxiety, Depression, Coagulopathies, Others
Must Not Be Taking:Opioids
80 Participants Needed
Myfembree for Fibroids
Schererville, IndianaThis trial is testing Myfembree, a pill that combines three medications, to help women who have had surgery for fibroids. The goal is to delay the return of fibroid symptoms and improve their quality of life. Myfembree works by lowering certain hormone levels and balancing others to reduce heavy menstrual bleeding and other symptoms.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18+
Sex:Female
Key Eligibility Criteria
Disqualifiers:Osteoporosis, Liver Disease, Cardiovascular, Others
Must Be Taking:Myfembree
136 Participants Needed
Green Tea Extract for Uterine Fibroids and Infertility
Chicago, IllinoisThis trial tests if a low caffeine green tea extract with high EGCG can help women aged 18-40 with fibroids get pregnant. The EGCG may shrink fibroids and improve the uterus lining, increasing pregnancy chances. EGCG, a major component of green tea, has been studied for its potential benefits in reducing uterine fibroids and improving reproductive health.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 40
Sex:Female
Key Eligibility Criteria
Disqualifiers:Pregnancy, Diabetes, Heart Disease, Others
Must Not Be Taking:Depo-progestins, Hormonal Implants
50 Participants Needed
Lifestyle Program for Endometrial Cancer Survivors
Charlottesville, VirginiaThe purpose of this study is to promote positive lifestyle change among endometrial cancer survivors by using a group-based intervention. Endometrial cancer survivors are at an increased risk of other health conditions like heart disease, diabetes, and other cancers. The study team at the University of Virginia wants to explore new ways to lower these risks. This study will be evaluating the Anticancer Lifestyle program, which takes a more holistic approach and uses web-based learning modules along with weekly group sessions to discuss each topic of the web-based learning modules.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18+
Sex:Female
23 Participants Needed
Simvastatin for Uterine Fibroids
Baltimore, MarylandThis trial is testing if simvastatin, a cholesterol-lowering drug, can reduce the size of uterine fibroids in women who are planning to undergo surgery. The study will see if simvastatin helps shrink the fibroids. Simvastatin is a well-known cholesterol-lowering drug that has been extensively studied for its effects on lipid profiles and cardiovascular health.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 55
Sex:Female
Key Eligibility Criteria
Disqualifiers:Pregnancy, Cancer, Menopausal, Others
Must Not Be Taking:Statins, CYP3A4 Inhibitors
60 Participants Needed
Methadone for Uterine Fibroids
Baltimore, MarylandCurrently, there is a nationwide epidemic of opioid abuse and overdose deaths. One source of excess opioids is overprescribing in the postoperative period. This study aims to find the optimal pain medication plan during and after laparoscopic hysterectomy to eliminate long-term opioid use.
Given the increasing opioid abuse and over-prescription post-operatively, an effort should be made to determine whether one time dosing of Methadone, a longer opioid analgesics, intra-operatively is an adequate potential in treating postoperative pain after hysterectomy surgeries. The investigators hypothesize that this could minimize the need for additional post-operative and outpatient opioid prescriptions and decrease the adverse effects that are associated with the consumption, including new opioid abuse.
Intervention group will receive methadone intraoperatively while the other group would receive short-acting opioids (standard).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:Female
100 Participants Needed
Steroid-Enhanced Nerve Block for Uterine Fibroids Pain Relief
Chapel Hill, North CarolinaThe purpose of the study is to investigate the differences in post-procedural pain scores and narcotic use among patients who receive a Superior Hypogastric Nerve Block (SHNB) with and without corticosteroid performed as part of the Uterine Artery Embolization (UAE) procedure.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Early Phase 1
Age:30 - 60
Sex:Female
28 Participants Needed
Perfluten for Uterine Fibroids
Philadelphia, PennsylvaniaThis study goals are to determine the patterns of uterine fibroid vascularity pre and post UAE using CEUS resulting in an alternative to gadolinium-enhanced MRI that is less expensive, has less contra-indications and side effects, is real time, and noninvasive helping physicians to evaluate the result of UAE procedures. Also, this study will evaluate uterine fibroid pressures using SHAPE, comparing the results with normal myometrium tissue in order to determine its characteristics and tissue differences, which we believe will lead to the development of a new biomarker for the diagnosis and treatment of uterine fibroids.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:Female
80 Participants Needed
Tranexamic Acid for Uterine Fibroids
Norfolk, VirginiaThis is a Double-blinded randomized placebo-controlled trial based at Eastern Virginia Medical School. Subjects who are identified in clinic having menorrhagia or abnormal Uterine bleeding (AUB) due to uterine fibroids and meet inclusion criteria based on the ultrasound (US) or Magnetic Resonance Imaging (MRI), aged 18-45 undergoing laparoscopic or Robotic assisted myomectomies. A total of 50 women in each arm of the study with symptomatic fibroids. Patients will be randomized to receive a single IV bolus injection of TXA 30mg/kg in 50ml of normal saline (intervention group) versus an IV bolus injection of normal saline of equivalent volume (placebo group) 15 minutes prior to initial surgical incision.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 45
Sex:Female
50 Participants Needed
Lifestyle Intervention for Uterine Fibroids
New York, New YorkThis trial is testing a program that includes changes to daily habits, diet, and physical activity for patients who have had fibroid removal surgery. The goal is to see if these changes can help prevent fibroids from coming back.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18 - 50
Sex:Female
100 Participants Needed
Liposomal Bupivacaine for Post-Surgery Pain in Fibroids
New York, New YorkThe study team will be randomizing patients presenting for open myomectomy to either received transversus abdominal plane blocks with either liposomal bupivacaine or standard bupivacaine. The study team will be analyzing the impact of local anesthetic on opiate consumption as the investigator's primary endpoint with other secondary endpoints.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 64
Sex:Female
Key Eligibility Criteria
Disqualifiers:Pregnancy, Epilepsy, Seizure Disorder, Others
140 Participants Needed
Ultrasound Imaging for Fibroids
Ottawa, OntarioUterine fibroids (leiomyomas, myomas, fibroids) are benign tumors of the uterus that can cause heavy menstrual bleeding, pain, and/or infertility. Fibroids can be managed with medication, surgery, or interventional radiology. While conservative methods that avoid surgical risks and complications are becoming more common, there are limitations to medical therapies including side effects, short durations of use, and incomplete response to treatment. To optimize patient outcomes, it is imperative clinicians and researchers better understand which patients may benefit from medical therapies and which may not. Fibroids with less blood supply can degenerate and take on a variety of histological characteristics (e.g. cystic, red, fatty, calcific) which may decrease response to medical management. These histological characteristics in degenerated fibroids correspond to altered mechanical properties, ranging from very soft to very hard. There is currently no guidance on how to predict medical responsiveness based on such fibroid characteristics. As a result, physicians treat patients empirically with medications, without the ability to counsel on effectiveness or failure rates. Our research goal is to understand if and how uterine fibroid tissue stiffness can predict response to medical therapies. To achieve this, the investigators will use a new ultrasound technology, called shear wave elastography (SWE), that non-invasively measures tissue stiffness and is currently used in practice for staging of chronic liver diseases; however, given that this technology is very new, evidence of its clinical application in gynecology is limited. Through implementing an innovative and multidisciplinary approach, the investigators will (1) systematically establish SWE as a feasible and reliable tool for measuring non-neoplastic myometrial and uterine fibroid tissue stiffness, and (2) use SWE to classify and monitor fibroid tissue properties in pre-menopausal women undergoing medical intervention for symptomatic uterine fibroids. Understanding the connection between pathological tissue properties and the success of medical therapies is essential to streamline assessment and intervention planning and improve overall patient outcomes for the many Canadian women who suffer from uterine fibroids.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:18 - 80
Sex:Female
60 Participants Needed
Vaginoscopy vs Traditional Hysteroscopy for Fibroids
Montreal, QuebecThis study is a randomized controlled trial take place in a fertility outpatient clinic in an academic hospital. Women between 18 and 52 years old requiring polypectomy or myomectomy by hysteroscopy morcellation for abnormal uterine bleeding or for fertility issue are included. The aim is to evaluate pain perception between vaginal and traditional hysteroscopy for hysteroscopic morcellation. The investigator's hypothesis is that pain perception is lower using vaginoscopy compared to traditional hysteroscopy.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18 - 52
Sex:Female
78 Participants Needed
TriNaV for Uterine Fibroids
Boston, MassachusettsThe goal of this study is to assess of Pressure-Enabled Drug Delivery on fibroid treatment in patients undergoing UFE.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 60
Sex:Female
Key Eligibility Criteria
Disqualifiers:Pregnancy, Adenomyosis, Endometriosis, Gynecologic Malignancy, Others
Must Not Be Taking:GnRH Agonists, GnRH Antagonists
20 Participants Needed
Letrozole for Uterine Fibroids
Jackson, MississippiThe PLUM Study is a randomized, double-blinded, 2-arm, parallel-group, placebo-controlled trial is designed to compare the efficacy of letrozole versus placebo on leiomyoma-related symptoms and quality of life as well as leiomyoma and uterine size.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:21 - 53
Sex:Female
Key Eligibility Criteria
Disqualifiers:Pregnancy, Breast Cancer, Osteoporosis, Others
Must Not Be Taking:Aromatase Inhibitors, SERMs, Estrogens, Methadone
140 Participants Needed
MABEL CTLs for EBV-Positive Lymphoma
Houston, TexasThe subject has a type of cancer or lymph gland disease associated with a virus called Epstein Barr Virus (EBV), which has come back, is at risk of coming back, or has not gone away after standard treatments. This research study uses special immune system cells called LMP, BARF-1 and EBNA1- specific cytotoxic T lymphocytes (MABEL CTLs).
Some patients with Lymphoma (such as Hodgkin (HD) or non-Hodgkin Lymphoma (NHL)), T/NK-lymphoproliferative disease, or CAEBV, or solid tumors such as nasopharyngeal carcinoma (NPC), smooth muscle tumors, and leiomyosarcomas show signs of a virus called EBV before or at the time of their diagnosis. EBV causes mononucleosis or glandular fever ("mono" or the "kissing disease"). EBV is found in the cancer cells of up to half the patients with HD and NHL, suggesting that it may play a role in causing Lymphoma. The cancer cells (in lymphoma) and some immune system cells (in CAEBV) infected by EBV are able to hide from the body's immune system and escape destruction. EBV is also found in the majority of NPC and smooth muscle tumors, and some leiomyosarcomas. We want to see if special white blood cells (MABEL CTLs) that have been trained to kill EBV infected cells can survive in your blood and affect the tumor.
In previous studies, EBV CTLs were generated from the blood of the patient, which was often difficult if the patient had recently received chemotherapy. Also, it took up to 1-2 months to make the cells, which is not practical when a patient needs more urgent treatment. To address these issues, the MABEL CTLs were made in the lab in a simpler, faster, and safer way. The MABEL CTLs will still see LMP proteins but also two other EBV proteins called EBNA-1 and BARF. To ensure these cells are available for use in patients in urgent clinical need, we have generated MABEL CTLs from the blood of healthy donors and created a bank of these cells, which are frozen until ready for use. We have previously successfully used frozen T cells from healthy donors to treat EBV lymphoma and virus infections and we now have improved our production method to make it faster.
In this study, we want to find out if we can use banked MABEL CTLs to treat HD, NHL, T/NK-lymphoproliferative disease, CAEBV, NPC, smooth muscle tumors or leiomyosarcoma. We will search the bank to find a MABEL CTL line that is a partial match with the subject.
MABEL CTLs are investigational and not approved by the Food and Drug Administration.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:All
Sex:All
38 Participants Needed
INCB000928 for Stone Man Syndrome
Toronto, OntarioThis trial is testing a new drug called INCB000928 to help people with a rare condition called fibrodysplasia ossificans progressiva (FOP). FOP causes soft tissues to turn into bone, and there are few treatments available. The study will check if the drug is safe and effective in stopping or slowing this abnormal bone growth.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:2 - 99
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, HIV, HBV, HCV, Others
Must Not Be Taking:Antibiotics, Antifungals, Antivirals
98 Participants Needed
HMI-guided Focused Ultrasound for Breast Cancer
New York, New YorkThe objective of this study is to demonstrate the initial clinical feasibility of using Harmonic Motion Imaging (HMI) for Focused Ultrasound Surgery (FUS) guidance and monitoring in patients with benign and stage 1 non-metastatic breast cancers. The investigators hypothesize that changes in HMI parameters will inform progression of FUS ablation.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:Female
Key Eligibility Criteria
Disqualifiers:Pregnancy, Breast Implants, Prior Radiation, Others
36 Participants Needed
Page 1 of 1+
Frequently Asked Questions
How much do Fibroid clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Fibroid clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Fibroid trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Fibroid is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Fibroid medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Fibroid clinical trials ?
Most recently, we added Methadone for Uterine Fibroids, Perfluten for Uterine Fibroids and Lifestyle Program for Endometrial Cancer Survivors to the Power online platform.